Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Total Liabilities (2020 - 2023)

Cullinan Therapeutics has reported Total Liabilities over the past 4 years, most recently at $25.9 million for Q3 2023.

  • Quarterly results put Total Liabilities at $25.9 million for Q3 2023, down 16.78% from a year ago — trailing twelve months through Sep 2023 was $25.9 million (down 16.78% YoY), and the annual figure for FY2022 was $26.1 million, up 120.88%.
  • Total Liabilities for Q3 2023 was $25.9 million at Cullinan Therapeutics, up from $22.4 million in the prior quarter.
  • Over the last five years, Total Liabilities for CGEM hit a ceiling of $62.6 million in Q2 2022 and a floor of -$106.8 million in Q1 2020.
  • Median Total Liabilities over the past 4 years was $14.4 million (2020), compared with a mean of -$1.9 million.
  • Biggest five-year swings in Total Liabilities: skyrocketed 977.43% in 2022 and later crashed 64.22% in 2023.
  • Cullinan Therapeutics' Total Liabilities stood at $14.4 million in 2020, then decreased by 17.94% to $11.8 million in 2021, then surged by 120.88% to $26.1 million in 2022, then dropped by 0.76% to $25.9 million in 2023.
  • The last three reported values for Total Liabilities were $25.9 million (Q3 2023), $22.4 million (Q2 2023), and $29.3 million (Q1 2023) per Business Quant data.